Rick Simpson Oil (RSO) in the U.S. Virgin Islands: The Complete Guide by OilWell Cannabis

For residents of St. Thomas, St. John, and St. Croix navigating chronic pain, cancer treatment support, sleep disorders, or the long shadows of PTSD, the search for effective relief often leads down winding paths. Many of you have watched friends or family members travel to mainland hospitals—Puerto Rico, Miami, Houston—seeking specialized care that simply isn’t available here at home. You’ve seen the toll that prescription medications take, the limitations of what our excellent but overstretched physicians at Roy L. Schneider Hospital can offer within the constraints of island healthcare logistics. And you’ve heard the whispers, increasingly becoming conversations, about cannabis oil—about something called RSO.

We understand. At OilWell Cannabis, we weren’t born in a corporate boardroom. We were born in the borderlands of McAllen, Texas, where healthcare gaps and economic hardship taught us that real medicine sometimes comes from unexpected places. We learned this lesson most profoundly through Bentley, a paralyzed dog who veterinarians said should be euthasized but who walked again after we created our first cannabinoid formula. That was ten years ago. That formula—born from desperation, refined through a decade of real-world testing, and anchored in the same evidence-based approach we apply to every product—has evolved into what we now bring to the U.S. Virgin Islands: a modern, legal, multi-cannabinoid RSO that respects Rick Simpson’s original vision while solving the problems that made traditional RSO dangerous and unreliable.

This guide is for the cancer patient in Charlotte Amalie wondering if there’s anything beyond chemotherapy’s side effects. For the veteran in Cruz Bay struggling with PTSD and the pharmaceutical treadmill. For the fisherman in Christiansted whose chronic back pain makes every morning a negotiation. For the caregiver in Frederiksted desperate for sleep after nights of tending to a loved one. We wrote this because you deserve complete, honest information—not marketing fluff, not snake oil promises, but the actual science, the real risks, the proven benefits, and the practical details of how our RSO can reach your doorstep in the Virgin Islands.

ABOUT RICK SIMPSON AND TRADITIONAL RICK SIMPSON OIL

Who is Rick Simpson

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He was not a doctor, scientist, or medical professional. He was a power engineer and maintenance worker—a blue-collar tradesman whose path into cannabis advocacy began not with research but with personal suffering and a deep distrust of the medical system that failed him. This matters for Virgin Islanders because many of you have experienced similar failures: diagnoses without good treatment options, specialists who are booked six months out, prescriptions that cause more problems than they solve.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t resolve. The medications prescribed either failed to help or made things worse. When he asked his physician about cannabis, the request was refused—an experience that resonates with many patients in the Virgin Islands who’ve found their doctors hesitant or unwilling to discuss cannabis options, even as a complementary therapy .

Simpson’s interest deepened after learning about a 1974 NIH study at the Medical College of Virginia, where THC reportedly slowed tumors in mice. That study—intended to demonstrate harm—became Simpson’s foundational reference, though its findings were never replicated in controlled human trials .

The pivotal moment came in 2003. Three bumps on his arm were diagnosed as basal cell carcinoma. Rather than conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions. According to his account, they disappeared in four days. No independent medical verification, biopsy confirmation, or clinical follow-up was ever published. This personal experience—unverified but emotionally powerful—became the origin story of Rick Simpson Oil .

Important context: Simpson’s account is personal testimony, not medical evidence. The absence of clinical documentation means these events cannot be evaluated as proof. They are, however, historically significant as the catalyst for a global movement—one that eventually reached the Virgin Islands through online communities, patient networks, and the documentary Run From The Cure that introduced RSO to the world .

The crusade — spreading the oil

After 2003, Simpson committed himself to producing and distributing concentrated cannabis oil from his property in Maccan, Nova Scotia. He gave it away for free to cancer patients and others in his community. By his account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and more .

His story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. Within cannabis communities, it was foundational—many Virgin Islanders first learned about RSO through this film, shared in Facebook groups, cancer support forums, and word-of-mouth networks that span our islands.

Simpson’s advocacy brought him into direct conflict with Canadian law. The RCMP raided his property in 2005 and 2009, seizing plants and equipment. He was charged with cultivation, possession, and trafficking. Facing continued legal pressure, Simpson left Canada for Europe, living in Croatia and the Netherlands, continuing his advocacy from abroad .

In 2012, he published Phoenix Tears: The Rick Simpson Story and maintained phoenixtears.ca as his primary platform . Throughout his career, Simpson maintained that cannabis oil could cure cancer and that pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge .

Important context: Simpson’s conspiratorial framing reflects a worldview shared by many in the early cannabis movement. It’s relevant to understanding RSO’s cultural significance, but it doesn’t change the evidence assessment.

The traditional RSO protocol — Simpson’s 60-gram, 90-day regimen

Simpson’s core recommendation was consuming 60 grams of concentrated oil over roughly 90 days. This protocol—often sought by Virgin Islands cancer patients through underground networks—was designed around crude, unstandardized material. Here’s the detailed breakdown :

Goal

Consume 60 grams of high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum for serious cancer treatment.

Titration schedule

• Week 1: Half a grain of rice-sized dose (10-15 mg) three times daily—total 30-45 mg/day
• Weeks 2-5: Double every four days, building tolerance gradually
• Weeks 5-12: Reach 1 gram (1,000 mg) per day, divided into three 333 mg doses
• Maintenance: After 60 grams, continue 1-2 grams/month indefinitely

Administration methods

• Oral (primary): Sublingual or swallowed—for systemic absorption and internal cancers
• Topical (secondary): Applied directly to skin lesions for external cancers, combined with oral dosing
• Inhalation (not primary): For immediate symptom relief only, not sustained treatment

Tolerance and psychoactive effects

Simpson claimed patients develop THC tolerance within 3-4 weeks and recommended nighttime dosing initially. He warned against driving during titration—a practical consideration for Virgin Islanders who must navigate our hilly, sometimes precarious roads .

Important context for evaluating this protocol

This protocol has never been validated in controlled trials. Critical issues:

• No clinical validation—no randomized trials, cohort studies, or documented case series
• Crude, unstandardized material—every batch differed based on starting plant material
• Extremely high THC exposure—600-900 mg delta-9 THC daily at peak dosing, far exceeding FDA-approved dronabinol (2.5-20 mg/day)
• Real risks—severe intoxication, anxiety, tachycardia, hypotension, cannabis use disorder [1][13][14][15]
• Oncology complexity—cancer patients are medically vulnerable; using unregulated oil as primary treatment risks delayed or foregone proven therapies

What is traditional Rick Simpson Oil — the product

Traditional RSO was defined by Simpson’s method, not lab specifications:

• Source material: Single high-THC indica strain, no standardization
• Extraction solvent: Naphtha (petroleum-based) or 99% isopropyl alcohol—not food-grade
• Process: Bucket, solvent wash, filter, rice cooker evaporation, syringe storage
• Appearance: Nearly black, thick, tar-like, sticky, strong cannabis/solvent odor
• Cannabinoid profile: 60-90% delta-9 THC, fully decarboxylated, minor cannabinoids at natural ratios—uncontrolled, unmeasured, never lab-verified
• Terpene content: Minimal to none—destroyed by solvent and heat
• Standardization: None. Every batch was different—no COA, no testing
• Residual solvent risk: Naphtha may contain benzene, toluene, other carcinogens. Purging was impossible to verify without lab testing

Simpson’s claims vs. the evidence record

Simpson claimed RSO could cure cancer and many diseases. Let’s examine what the evidence actually shows:

What Simpson was not

He had no formal medical, oncology, pharmacology, or research training. He never conducted or published a clinical trial. His evidence was personal experience and testimonials—no controls, no verification, no blinding.

What the preclinical literature shows

• THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines
• Animal models show some tumor-growth inhibition
• These findings are scientifically interesting but have not translated to proven human cancer cures

What the preclinical literature does NOT show

• No human clinical trial has demonstrated RSO or any cannabis oil cures cancer
• The gap between animal results and human outcomes is vast
• Small human trials in glioblastoma have been exploratory and inconclusive

Institutional positions

• National Cancer Institute (NCI): Acknowledges anticancer research but does not endorse cannabis as cancer treatment
• FDA: Has not approved any cannabis plant product for cancer. Only Epidiolex (CBD) for seizures and synthetic THC analogues for chemo nausea/AIDS wasting are approved [1]
• Health Canada: Never approved RSO for cancer
• NCCIH: Strongest evidence is for rare epilepsies, chemo nausea, and HIV/AIDS appetite—not cancer cure [1]

What Simpson got right

He drew attention to cannabinoids as serious biomedical research when the world ignored them. His advocacy helped create the conditions for today’s legal cannabis industry and research infrastructure. The term “RSO” remains the most recognized name for full-spectrum cannabis extract .

What he overstated

The leap from preclinical signals to cancer cure was never supported by human evidence. Encouraging cancer patients to rely on RSO instead of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed treatment for treatable cancers is a documented concern in alternative medicine.

The legacy of Rick Simpson and the evolution of modern RSO

The term “RSO” is now generic. Many products labeled RSO bear little resemblance to Simpson’s original oil. In Virgin Islands dispensaries (if and when they open), “RSO” could mean almost any full-spectrum extract .

Simpson has been critical of commercial products departing from his method and philosophy. He gave oil away for free; the industry commercialized it. This tension—improvement through quality control vs. betrayal through profit—divides the cannabis community .

What is not disputed: modern RSO has evolved substantially, and those changes matter for Virgin Islands consumers seeking safe, effective products.

Traditional RSO vs. modern formulated RSO

Dimension	Traditional RSO	OilWell formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing for potency, safety
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge
THCa preservation	No—fully decarboxylated by heat	Yes—THCa included as separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s formulas diverge from traditional RSO

Our formulations intentionally depart from Simpson’s method in evidence-motivated ways:

• Multi-cannabinoid approach: Traditional RSO used whatever single strain was available. Our formula includes seven cannabinoids—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—reflecting entourage-effect literature suggesting potential benefit from diversity [20][29].

• Terpene preservation: Traditional RSO had essentially no terpenes. We include live terpenes at 5% with a specific seven-terpene profile because preclinical literature suggests terpene bioactivity is plausible, even if human clinical confirmation remains limited [20][21][23][24][25][26][27][28][29].

• THCa as separate ingredient: Traditional RSO fully decarboxylated everything. Our sublingual formula includes 1,500 mg THCa in its acidic form, preserving non-psychoactive potential that is lost when THCa converts to THC [12].

• Reduced delta-9 THC dominance: Traditional RSO was 60-90% delta-9 THC. Our formula uses only 90 mg delta-9 THC while incorporating 6,000 mg delta-8 THC and other cannabinoids—reflecting broader research rather than single-compound dominance.

• Product format innovation: Simpson had one crude format. We offer both sublingual oil (sustained relief) and vape cartridge (fast relief), acknowledging different pharmacokinetic profiles [14].

Solvent safety and extraction evolution

Traditional RSO’s naphtha or isopropyl alcohol left toxic residues. Naphtha contains benzene, toluene, and other carcinogens. Purging was impossible to verify without lab equipment.

Modern extraction uses food-grade ethanol or supercritical CO₂, allowing complete solvent removal and validated testing via headspace gas chromatography. This is one of the clearest safety improvements over traditional RSO [1][10][11][14].

The decarboxylation question

Traditional RSO was fully decarboxylated—heat converted all THCa to THC. Our sublingual formula preserves THCa at 1,500 mg as a distinct ingredient. The significance:

• Raw (non-psychoactive): All 1,500 mg stays as THCa—providing potential anti-inflammatory and neuroprotective benefits via COX-2 inhibition and PPARγ agonism without impairment [12].
• Activated (home decarboxylation): Heating at 260°F (125°C) for 45-60 minutes converts 1,500 mg THCa to ~1,315 mg delta-9 THC. Combined with existing 90 mg delta-9, this yields ~1,405 mg total delta-9 THC—full psychoactive potency comparable to illegal RSO, entirely at your discretion.
• Partial activation: Transfer a portion to an oven-safe container, decarb only what you intend to use, preserve the rest raw.

The conversion ratio: 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation (accounting for CO₂ loss).

For Virgin Islands residents, this means one purchase serves multiple needs—daytime functional use (raw) for work, driving, parenting; nighttime full-potency use (decarbed) for therapeutic strength; instant relief (vape) for acute situations.

Terpene loss in traditional RSO

Terpenes volatilize at 21-157°C. Traditional RSO’s solvent evaporation destroyed them, leaving a cannabinoid-only product. Our formula includes live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene. Each has its own evidence profile in our GENERAL KNOWLEDGE section.

Evidence standards then and now

Rick Simpson operated pre-legalization, pre-testing, pre-research. His evidence was anecdotal. This document uses formal evidence hierarchy: human clinical evidence → systematic reviews → institutional summaries → preclinical literature [1]-[29].

We honor Simpson’s origin story while committing to modern cannabinoid science standards—essential for Virgin Islands patients making informed decisions.

Simpson’s protocol vs. modern dosing considerations

Simpson’s protocol was designed for crude, variable extract. Our standardized multi-cannabinoid formulation requires different dosing:

• Our concentration: 553 mg total cannabinoids per mL
• Our delta-9 THC: Only 90 mg total in bottle (vs. Simpson’s 600-900 mg/day)
• Our approach: Start low, go slow—0.25-0.5 mL sublingual, assess over 2-3 hours before increasing

Virgin Islands residents should consult local healthcare providers when developing dosing strategies, especially if receiving treatment at Roy L. Schneider Hospital or traveling to mainland specialists.

ABOUT OILWELL CANNABIS AND THE OILWELL RSO FORMULA

The origin of OilWell Cannabis

We founded OilWell Cannabis in Houston, Texas, but our story begins in McAllen—right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa Borderplex is one of the most economically challenged and dangerous regions along the U.S.-Mexico border, marked by poverty, cartel violence, and limited opportunities beyond retail and healthcare. Reynosa’s industrial landscape is harsh; McAllen’s economy struggles with inequality.

Our founder, Colin Valencia, grew up in this environment. By sixteen, after facing every form of violence imaginable and watching best friends killed or imprisoned, he had to leave home for good. He learned to hustle in the border’s gray economy, but chose cannabis over darker paths—seeing it as safer and more beneficial. This wasn’t a corporate origin story; it was survival.

Colin later became a formally trained software engineer, doing custom development work for Baylor College of Medicine in the Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—defines our approach. When we say we understand both the plant and the science, it’s because we’ve lived both.

Bentley’s story: where our formulas were born

Our company began with a dog named Bentley. He wasn’t just a pet; he was family. When Bentley fell seriously ill—paralyzed in his back legs—veterinarians delivered the verdict every pet owner dreads: euthanasia was the only humane option. The pain medications would destroy his internal organs, causing more suffering. The choice was painful decline or immediate mercy killing.

Colin refused. Bentley was a fighter, and after hearing a rescue worker ask, “You’ve moved how many tons of weed and you’ve never heard of CBD?” Colin discovered therapeutic cannabinoids. He created CBD golden paste—a specialized formula for pets. It wasn’t a cure, but it was a lifeline. And it delivered what veterinary medicine said was impossible: Bentley got up, walked over, and brought his ball to play.

Dogs don’t respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, dying naturally at age twenty. During those years, Colin developed specialized formulas for every age-related condition Bentley faced:

• Neurodegeneration → CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection
• Dementia → CBC’s role in neurogenesis
• Glaucoma → THC’s CB1 agonism for intraocular pressure reduction
• Crippling arthritis → Multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene through different receptor systems

Single cannabinoids weren’t enough. Bentley’s conditions required multi-cannabinoid synergy. Pharmaceutical precision mattered—Bentley’s life depended on formula accuracy, not guesswork. That ten-year R&D process on a patient we loved more than anything is why our RSO contains seven cannabinoids, not one or two.

Colin’s personal journey: PTSD, benzo addiction, and Peace

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey—a feat notoriously difficult and dangerous—using the cannabinoid knowledge developed keeping Bentley alive.

The Peace Gummies formula was created during midnight experiments while fighting through benzo withdrawal. Colin personally uses the vape form for insomnia and severe PTSD. This is not theoretical knowledge. He lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

Over time, doctors began using our formulas for Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. We’ve developed formulations for vegans, diabetics, and those with specific health needs—because in the Virgin Islands, where dietary restrictions and chronic disease management intersect with limited local resources, customization matters.

ABC13: Houston’s media validation

ABC13 KTRK Houston—America’s fourth-largest city’s number-one news source—featured Colin and OilWell in seven comprehensive segments from 2019 to 2023. Five different reporters covered business, law, medicine, community health, and politics. No other Houston cannabis operator has that frequency or breadth.

Key moments:

• September 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.” This quote is our north star.
• August 2021: We gave away 1,000 caviar pre-rolls (~$35,000 in product) to encourage COVID vaccination, coordinated with the city of Houston, with no political agenda.
• October 2021: When Texas banned Delta-8 overnight, we proactively removed all products before enforcement and warned other operators who were unknowingly shipping Schedule I narcotics—absorbing major revenue loss to act ethically.
• October 2022: ABC13 revealed Colin’s personal marijuana conviction history, adding weight to every quote about therapy and education. He said: “I would love to see people not get hurt for this anymore.”

These features weren’t purchased—they were earned through consistent expertise and community action.

Current operations

We operate from Montrose, Houston (810 Richmond Avenue, Houston, TX 77006) since 2019, generating ~$1M annual revenue with a near-5.0 Google rating. We’re Texas DSHS licensed. All artwork, formulations, and packaging are created in-house in Houston—no white-label products, no outsourced formulas. Just our recipes and ideas, brought to life with Houston grit and McAllen roots.

The OilWell RSO philosophy

Our RSO is not traditional RSO. It’s informed by the tradition but deliberately different in evidence-motivated ways:

1. Accessibility over gatekeeping. No medical card required. Age 21+ only. We ship nationwide and internationally. For Virgin Islanders, this means no need to fly to Puerto Rico or Florida for a medical card—legal access from your home in St. Thomas, St. John, or St. Croix.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for daytime functionality or decarboxylate it into delta-9 THC for full nighttime potency. For island residents who work in tourism, drive our winding roads, or parent active children, this control is essential.

3. Open-source formulas. We publish our complete formulas publicly—every cannabinoid, every milligram—so if you can’t afford our products, you can source ingredients and make your own. In the Virgin Islands, where economic disparity is real and shipping costs add up, this matters.

4. Evidence-informed, not evidence-overstating. The GENERAL KNOWLEDGE section that follows represents our commitment to honest education about what science actually says—essential for Virgin Islands patients making high-stakes decisions.

Farm Bill compliance and the THCa legal framework

The 2018 Farm Bill legalized hemp-derived products containing less than 0.3% delta-9 THC federally. This applies to U.S. territories, including the Virgin Islands.

Our RSO Sublingual Oil contains only 90 mg delta-9 THC in the entire 30 mL bottle—3 mg/mL—well under the 0.3% threshold. All cannabinoids are hemp-derived. The product is legal under federal law and in most jurisdictions.

THCa is the game-changer. THCa (tetrahydrocannabinolic acid) is the non-psychoactive precursor to delta-9 THC. It’s Farm Bill compliant at sale because it isn’t delta-9 THC yet.

You can legally purchase, possess, and transport our product, then decarboxylate THCa into delta-9 THC at home by heating at 260°F (125°C) for 45-60 minutes. This converts 1,500 mg THCa into ~1,315 mg delta-9 THC. Combined with the existing 90 mg, you get ~1,405 mg total delta-9 THC—full psychoactive potency comparable to illegal RSO, entirely your legal choice after purchase.

Important legal notice: THCa converts to delta-9 THC when heated. You are responsible for understanding and complying with Virgin Islands law. We ship with full documentation, COAs, and receipts. International customers (including those in the British Virgin Islands or other Caribbean jurisdictions) accept all customs and legal responsibility. Contact us at (832) 416-2816 or [email protected] to verify shipping feasibility to your specific island location.

Open-source formulas — why we publish everything

We publish our complete RSO formulas publicly. If you can’t afford $129.99 for sublingual oil or $49.99 for the vape cartridge, you can see exactly what’s inside, source individual distillates, and make your own. This echoes Rick Simpson’s original ethos—he gave oil away free and taught people to make it. We adapted that for the modern marketplace: sell a professional, tested product and publish the recipe.

As Colin said in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

The Bentley golden paste recipe (our original open-source formula):

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup unrefined organic coconut oil
• 1-2 teaspoons freshly ground black pepper (for absorption)
• CBD oil (dosage depends on pet size; consult veterinarian)

Instructions:

1. Mix turmeric and water in saucepan over low heat, stirring continuously until thick paste forms (7-10 minutes)
2. Add coconut oil and pepper; stir until thoroughly mixed
3. Cool and store in jar with lid (refrigerate up to 2 weeks)
4. Add CBD oil to paste before serving; start low and increase gradually

Serving: Mix small amount with pet’s food 1-2x daily. Monitor and consult veterinarian. This is the formula that saved Bentley—the foundation of everything we do.

The decarboxylation choice — patient-controlled potency

Traditional RSO was always fully psychoactive. Our sublingual formula gives you three options:

Option 1 — Raw, no heat: 1,500 mg THCa stays non-psychoactive. Provides potential anti-inflammatory benefits via COX-2 inhibition and neuroprotective effects via PPARγ agonism [12]. Perfect for Virgin Islands residents who work in tourism, operate boats, drive our winding island roads, or need daytime functionality without impairment.

Option 2 — Fully activated, home decarboxylation: Heat at 260°F for 45-60 minutes converts 1,500 mg THCa to ~1,315 mg delta-9 THC. Combined with existing 90 mg, yields ~1,405 mg total delta-9 THC. This achieves psychoactive potency comparable to traditional illegal RSO—100% legally, because activation happens after purchase.

Option 3 — Vape, auto-decarboxylation: Our RSO Vape Cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each puff. Fastest onset available.

Chemistry: THCa MW = 358.47 g/mol. Conversion ratio: 1 mg THCa = 0.877 mg delta-9 THC.

Solvent-free production

Our RSO is a formulated blend of individual cannabinoid distillates—no naphtha, no isopropyl alcohol, no butane. This eliminates residual solvent risk, one of traditional RSO’s most significant safety concerns.

We use organic MCT oil as carrier—a food-grade lipid that facilitates sublingual absorption and provides neutral taste, a huge improvement over traditional RSO’s tar-like consistency and solvent odor.

Third-party lab testing covers:

• Cannabinoid potency (±2% accuracy via HPLC/UHPLC)
• Terpene profile
• Heavy metals screening (arsenic, cadmium, lead, mercury via ICP-MS)
• Pesticide analysis (400+ compounds via LC-MS/MS and GC-MS/MS)
• Residual solvents (FDA Class 3 limits <5,000 ppm via headspace GC)
• Microbial contaminants (E. coli, Salmonella, Aspergillus)

COAs are available on request and through our website.

The broader OilWell product portfolio

Beyond RSO, we produce:

Asshole Peach — Our most popular product. Carefully formulated for euphoric, long-lasting sensation. Particularly favored by veterans for PTSD and pain relief without excessive sedation.

Peace Gummies — Developed from Colin’s personal benzo withdrawal experience. Helps manage insomnia and severe PTSD. Available in gummy and vape forms.

Custom creations — We design tailored products for specific cannabinoid ratios, delivery formats, or health needs, including vegan and diabetic formulations. For Virgin Islands residents with unique dietary restrictions or health profiles, this customization can be crucial.

Two product formats

RSO Sublingual Oil — $129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg/mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%
• Organic MCT oil base
• Graduated dropper (0.1 mL increments)
• Onset: 15-45 minutes
• Peak: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19%
• 40-60 doses per bottle

RSO Vape Cartridge — $49.99

• 1 gram cartridge
• 900+ mg total cannabinoids
• Same six-cannabinoid ratio (auto-decarbs THCa)
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1-2 minutes (fastest method)
• Peak: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35%

When to use each format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset—critical for breakthrough episodes
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration—covers overnight or work shift
Maximum bioavailability	Sublingual	13-19% absorption
Portability/discretion	Vape	Compact, no measuring—fits island lifestyle
Precise dosing control	Sublingual	0.1 mL graduated dropper
Daytime non-psychoactive	Sublingual (raw)	Zero impairment for work, driving, parenting
Nighttime psychoactive	Sublingual (decarbed) or Vape	Full therapeutic strength for sleep

Competitive comparison — OilWell RSO vs. alternatives

vs. Texas TCUP dispensary RSO (e.g., Texas Original)

Dimension	TCUP RSO	OilWell RSO
Cannabinoid profile	THC-only (420 mg/0.5g)	7 cannabinoids
CBG/CBN/CBC	0 mg	3,000 mg / 750 mg / 750 mg
Patient-controlled potency	No—always psychoactive	Yes—THCa raw or decarbed
Access requirements	Medical card + qualifying condition	Age 21+ only
Qualifying conditions	Cancer, PTSD, epilepsy, etc.	None required
Delivery	Travel to dispensary	Ships to Virgin Islands
Farm Bill compliant	No—state medical program	Yes—<0.3% delta-9 THC

vs. hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus (10 mL, 1,000 mg)	OilWell (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD	~950 mg	4,500 mg
CBG/CBN/Delta-8	Minimal	3,000 mg / 750 mg / 6,000 mg
THCa conversion	Minimal	1,500 mg (→1,315 mg delta-9)
Psychoactive option	No meaningful effect	Yes—via decarboxylation
Approximate price	$40-50	$129.99

Condition-specific usage context

Important disclaimer: These contexts are informed by research in our GENERAL KNOWLEDGE section. They are not medical prescriptions, not FDA-approved, and not substitutes for professional care. Our products are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before use, especially if receiving treatment at Roy L. Schneider Hospital or traveling to mainland specialists. Do not operate vehicles or machinery while under psychoactive cannabinoids.

Chemotherapy-related nausea and appetite support

• Pre-chemo: 0.5-1.0 mL sublingual 1 hour before treatment
• Breakthrough nausea: 2-3 vape puffs (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)
• Evidence: delta-8 antiemetic [9], delta-9 nausea control [1][13], CBD anxiolytic buffering [3]

Chronic pain (fibromyalgia, arthritis, neuropathy)

• Daytime: 0.3-0.5 mL raw sublingual—anti-inflammatory without impairment
• Nighttime: 0.5-1.0 mL decarbed sublingual—pain relief + CBN sleep support
• Breakthrough pain: Vape as needed
• Evidence: CBD pain relief [4], delta-9 pain control [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Sleep support

• Before bed: 1.0-2.0 mL sublingual
• 2.0 mL delivers 50 mg CBN—dosage investigated in 2024 sleep literature
• 1.0 mL delivers 25 mg CBN—above threshold associated with reduced sleep disturbance [16][17]

Anxiety and stress

• Daytime: 0.3 mL raw sublingual—CBD and CBG without psychoactivity
• Nighttime: 1.0 mL sublingual—full profile including CBN
• Evidence: CBD anxiety reduction [3], CBG pharmacology [7][8], limonene entourage effects [20]

General titration principle: Start low, go slow. Begin with 0.25-0.5 mL sublingual. Assess effects over 2-3 hours before increasing. Individual responses vary by weight, metabolism, tolerance, and concurrent medications.

Delivery and global accessibility

We operate the only same-day RSO delivery system in Houston, but for Virgin Islands residents, we offer reliable shipping that respects island realities.

U.S. Virgin Islands shipping:

• USPS Priority Mail: 3-5 business days to St. Thomas, St. John, St. Croix
• FedEx/UPS Ground: 4-6 business days
• Discreet packaging: No cannabis branding visible
• Tracking provided: For all orders
• Temperature-stable packaging: Essential for Caribbean heat
• Signature-required option: Available for security

International shipping to Caribbean neighbors:
We ship to multiple Caribbean nations. For British Virgin Islands or other jurisdictions, packages include full documentation, COAs, and receipts for customs. You are responsible for verifying local legality and accepting all customs risk. Contact us to discuss feasibility.

Important for Virgin Islands customers:

• Minimum shipping fee: $15 flat rate to USVI
• Free shipping: On orders over $200
• Hurricane season: We monitor weather; shipments may be delayed during storms
• Customs: As a US territory, USVI shipments face no customs duties, but packages are subject to inspection

The significance for Virgin Islanders: Rick Simpson couldn’t ship his oil anywhere—it was Schedule I, illegal to produce, possess, or transport. A cancer patient on St. Thomas, a chronic pain sufferer on St. John, or a veteran on St. Croix can now legally access the same clinical-strength multi-cannabinoid RSO that Houston patients receive. We built a product that can cross waters legally, completing a piece of Simpson’s vision that prohibition made impossible.

Our PANDEM1C SEO technology—a proprietary system with 14 million geopolitical locations and 300+ AI models—makes our products discoverable to Virgin Islands residents searching in your own terms, in your own time zone.

How the OilWell formulas connect to the evidence

Every cannabinoid in our formula (CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC) has its own evidence profile in our GENERAL KNOWLEDGE section below. Every terpene (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene) is covered with preclinical and review-level evidence.

Our formulas are anchored to per-compound evidence summaries that explain what’s well-supported, what’s emerging, and what’s overstated. We hold ourselves to the same evidence standards we apply to the broader field. That’s intentional. As Colin said in 2019: “People need the best possible version to base their opinions off of to give it a fair shot.”

OilWell is more than a brand—we’re a promise to deliver the most thoughtful cannabis products available, with the same integrity that defined us from the day Bentley got up and walked.

MEDIA RECOGNITION AND COMMUNITY IMPACT

Colin Valencia: Houston’s go-to cannabis authority

Between September 2019 and April 2023, ABC13 Houston featured Colin Valencia and OilWell Cannabis in seven distinct news segments. Five different reporters sought us out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or breadth.

These features document a consistent pattern: when ABC13 needed to explain cannabis to its audience, it called Colin. When Delta-8 legality changed overnight, it called Colin. When President Biden announced marijuana pardons, it called Colin—because he has personally lived with a cannabis conviction and could speak to the real impact.

The seven features:

1. September 15, 2019: “Texas CBD businesses booming”—Foundational quote: “I’m not trying to sell people snake oil…”
2. March 22, 2021: “Entrepreneur creates direct-to-consumer business”—”Pain comes in a lot of different forms”
3. May 24, 2021: “What is Delta 8 THC”—Iconic “Maybe you want to get high” exchange
4. August 20, 2021: “Houston CBD shop giving away free products for COVID vaccine”—$35,000 in product donated
5. October 19, 2021: “Texas ban over once legal hemp product Delta 8″—Proactive removal before enforcement
6. October 7, 2022: “Biden marijuana pardon”—Revealed Colin’s personal conviction history
7. April 21, 2023: “Marijuana industry getting creative”—Colin’s “Renaissance” framing

Complete Colin Valencia quote index (chronological):

1. “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”
2. “Pain comes in a lot of different forms.”
3. “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”
4. “We just want Houston to be as healthy as possible. We’re not doctors. We’re not experts on this . We don’t have any political agenda.”
5. “[We’re] trying to get the city behind me to help as many people as we can.”
6. “It’s going to be a surprise to a lot of people.”
7. “It was a prime seller and a prime interest of customers…”
8. “So those people are now, because they didn’t know, shipping Schedule 1 narcotics…”
9. “It’s disappointing, but I’m not going to lose my customers…”
10. “You face challenges with housing, loans, and banking…”
11. “I would love to see people not get hurt for this anymore.”
12. “I want it to be legalized… If you really look at what’s here now, there’s nothing you could show me that I could accomplish with what literally we have right now.”
13. “Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”

Key facts from media record:

• OilWell operates from 810 Richmond Avenue, Houston, TX 77006
• Texas DSHS licensed since 2019
• ~$1M annual revenue, near-5.0 Google rating
• Products sold at HydroShack Hydroponics (Heights)
• Partnered with The Game on Delta-8 caviar pre-rolls
• Coordinated with city of Houston for vaccination efforts
• Proactive ethical action during Delta-8 ban crisis
• Colin has personal marijuana conviction history (revealed 2022)

The through-line: These features reveal consistency across years, breadth of expertise, documented community action, personal stakes, and evolution of language. This recognition cannot be purchased—only earned.

GENERAL KNOWLEDGE

Research method and evidence weighting

We prioritize sources in this order: human clinical evidence, systematic reviews/meta-analyses, NIH/institutional summaries, then mechanistic/preclinical literature when human data are sparse. This matters because the evidence base is uneven—CBD and delta-9 THC have the strongest human data; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes rely more on reviews, animal work, and early translational literature [1]-[29].

Institutional baseline from NIH and related sources

• NCCIH states strongest cannabinoid evidence is for rare epilepsies, chemo nausea/vomiting, and HIV/AIDS appetite. Modest evidence exists for chronic pain and MS symptoms. Many claimed uses remain early-stage [1].
• FDA has not approved the cannabis plant itself for medical use. Only Epidiolex (CBD) for seizures and synthetic THC analogues for chemo nausea/AIDS wasting are approved [1].
• Safety concerns highlighted by NIH include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy concerns, accidental pediatric exposure, contamination, and THC-vape lung injury [1].
• NCCIH warns OTC CBD products may differ from labels and can cause decreased alertness, GI effects, liver abnormalities, and drug interactions [1].

Cannabinoids

CBD

• Strongest evidence in our formula set, especially as purified product [1]-[6]
• Best supported: Seizure disorders (Epidiolex) [1][2]
• Anxiety: 2024 meta-analysis of 316 participants showed significant anxiolytic signal but stressed limited clinical sample [3]
• Pain: 2024 systematic review found promising but heterogeneous evidence, limiting broad analgesic claims [4]
• Sleep: 2023 review found methodologically weak literature with few objective assessments [5]
• Safety: 2023 meta-analysis found liver enzyme elevation and possible drug-induced liver injury risk, especially relevant for concentrated oral products and polypharmacy [6]
• Bottom line: Most evidence-developed nonintoxicating cannabinoid, but strong evidence is indication-specific, not generalized wellness [1]-[6]

CBG

• Evidence profile: Mostly review/preclinical; human evidence sparse [7][8]
• Pharmacology: Biosynthetic precursor with distinct receptor interactions (CB1/CB2, alpha-2 adrenoceptors, 5-HT1A) [7]
• Research areas: Neurologic disorders, inflammatory bowel disease, antibacterial activity—but primarily preclinical hypotheses [7][8]
• Caution: Commercially sold while evidence base remains thin [7]
• Bottom line: Promising minor cannabinoid with limited clinical validation [7][8]

Delta-8 THC

• Evidence profile: Pharmacologically relevant, psychoactive, less clinically characterized than delta-9 [9]-[11]
• Comparative pharmacology: 2022 review found similar PK/PD to delta-9 but less potent, likely due to weaker CB1 affinity [9]
• Public health: 2023 scoping review found evidence base dominated by animal studies and use reports, with adverse consequence reports [10]
• Manufacturing: Greater stability and easier synthesis than natural plant levels; raises product-byproduct and testing concerns [11]
• Bottom line: Psychoactive THC analogue with real activity but incomplete safety characterization and quality concerns [9]-[11]

THCa

• Evidence profile: Important chemically but low on direct human therapeutic evidence [12]
• What it is: Acidic precursor representing large share of raw plant THC content; decarboxylates to THC with heating/time [12]
• Psychoactivity: Does not produce THC’s psychoactive effects if it stays acidic, but conversion is common [12]
• Research: In vitro/rodent studies suggest anti-inflammatory, immunomodulatory, neuroprotective, antineoplastic possibilities—but not established human outcomes [12]
• Bottom line: Relevant precursor whose interpretation depends on route, temperature, processing, storage [12]

Delta-9 THC

• Evidence profile: Strongest human evidence of psychoactive cannabinoids, but clearest adverse-effect burden [1][13]-[15]
• Institutionally supported: Chemo nausea/vomiting, HIV/AIDS appetite, some MS/pain outcomes [1]
• Pain evidence: 2022 systematic review found high-THC products may provide short-term pain benefit but increase dizziness, sedation, nausea, discontinuation [13]
• Pharmacokinetics: Inhaled onset seconds-minutes, peak 15-30 min, duration few hours; oral onset later, peak later, longer duration [14]
• Mental health risk: 2025 systematic review found consistent unfavorable associations with psychosis/schizophrenia and cannabis use disorder, plus anxiety/depression signals [15]
• Broader safety: Anxiety/panic at high doses, tachycardia, blood pressure changes, dependency, withdrawal, pregnancy concerns, vape lung injury [1][14][15]
• Bottom line: Legitimate therapeutic relevance in some settings, but carries clearest intoxication, psychiatric, and dose-related safety liabilities [1][13]-[15]

CBN

• Evidence profile: Weak human evidence; marketing ahead of data [12][16][17]
• Marketing vs. reality: Widely touted for sleep, but clinical support is thin [16][17]
• Sleep claim review: 2021 review screened 99 human-study abstracts, reviewed 8 full-text articles, found no clinical trials using validated sleep questionnaires or polysomnography to substantiate strong sleep-promoting claims [16]
• Broader sleep literature: 2024 updated review concluded cannabinoid sleep research still doesn’t match real-world use scale; need for better-designed trials remains substantial [17]
• Chemical context: THC degrades toward CBN under certain conditions, linking CBN to aging cannabis chemistry [12]
• Bottom line: Clearest example where cultural reputation exceeds current clinical evidence [16][17]

CBC

• Evidence profile: Emerging, intriguing, overwhelmingly preclinical/review-based [18][19]
• Pharmacology: 2024 review describes distinct PK/PD, receptor behavior; highlights antinociceptive, antibacterial, anti-seizure potential [18]
• Older literature: Anti-inflammatory, reduced gut hypermobility, modest rodent analgesia, possible neurobiological/antiproliferative relevance—but not strong patient-facing evidence [19]
• Safety caveat: 2024 review notes OTC CBC products sold despite little clinical efficacy/safety evidence [18]
• Bottom line: Scientifically credible minor cannabinoid deserving more research, not already-validated clinical active [18][19]

Terpenes

Terpene claims need stricter interpretation than cannabinoid claims. Most literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models. Robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene

• Evidence profile: Review/preclinical, useful safety literature [20]-[22]
• Potential activity: 2021 review describes antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immunomodulatory—but mostly nonhuman/non-cannabis [21]
• Safety note: Limonene oxidation products (hydroperoxides) are clinically relevant contact allergens [22]
• Bottom line: Biologically active but cannabis-specific therapeutic claims should stay conservative [20]-[22]

Myrcene

• Evidence profile: Mostly preclinical, very limited human evidence [20][23]
• Research: 2021 review describes anxiolytic, antioxidant, anti-inflammatory, analgesic—but explicitly states human studies lacking [23]
• Interpretation caution: Often invoked as proven sedative explaining “couch-lock”—stronger claim than evidence supports [20][23]
• Bottom line: Plausible bioactivity, but compound-specific clinical claims remain ahead of definitive proof [23]

Caryophyllene

• Evidence profile: Among most mechanistically interesting due to CB2 receptor agonism, but mostly preclinical [24]
• Why it stands out: 2021 review describes beta-caryophyllene as selective CB2 agonist—unusual, pharmacologically relevant [24]
• Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective—but human clinical confirmation limited [24]
• Bottom line: Strongest candidate for terpene with cannabinoid-system significance, but not clinically proven for common outcomes [24]

Pinene

• Evidence profile: Promising preclinical, weak human confirmation [20][25]
• Brain-health framing: 2021 review found antioxidant, anti-inflammatory, neuroprotective signals justifying future study, but emphasized lack of robust clinical trials [25]
• Interpretation caution: Claims that pinene improves memory, sharpens attention, or counterbalances THC cognitive effects remain hypotheses, not settled facts [20][25]
• Bottom line: Deserves scientific attention, but strong cognition claims should be presented as exploratory [25]

Linalool

• Evidence profile: Substantial preclinical interest, limited direct clinical confirmation [20][22][25][26]
• Research: Discussed for stress, mood, brain-health pharmacology. 2021 brain-health review found enough preclinical signal to justify continued investigation while emphasizing lack of robust human trials [25]
• Additional literature: Separate reviews discuss antidepressant mechanisms and neuropharmacologic relevance—but translational rather than definitive [26]
• Safety note: Oxidized linalool hydroperoxides are recognized allergens [22]
• Bottom line: Scientifically credible bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26]

Humulene

• Evidence profile: Translationally interesting, early stage [20][27]
• Scoping-review findings: 2024 review of 340 articles found broad preclinical evidence for anti-inflammatory effects, some rodent work suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27]
• Interpretation caution: Valuable for hypothesis generation, but doesn’t establish consistent human efficacy [27]
• Bottom line: More interesting terpene research target, but far from clinically settled [27]

Terpinolene

• Evidence profile: Among least clinically characterized in this file [20][28]
• Systematic-review findings: 2021 review screened 2,449 records, included 57 studies, concluded evidence base dominated by in silico, in vitro, animal studies—not human trials [28]
• Interpretation caution: Even recent entourage reviews frame terpene benefits as exploratory [20]
• Bottom line: Biologically interesting, but especially underdeveloped clinically [20][28]

Research limits and interpretation

1. Evidence base is highly uneven. CBD and delta-9 THC support most detailed statements; others require more caution [1]-[29].
2. Extract/molecule/synthetic/terpene data aren’t interchangeable. Common error: letting evidence from one category stand for another.
3. Minor cannabinoids/terpenes are commercially interesting because underexplored—but claims often become inflated.
4. Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent PK all affect real-world interpretation [1][10][11][14].
5. For THCa, chemistry is destiny. Storage and heating change exposure profile by converting acidic cannabinoids to neutral forms like THC [12].

Common overstatements to avoid

• Overstatement: CBN is clinically proven sleep aid.
  More accurate: Sleep evidence for CBN remains weak; no strong validated-trial base identified [16][17].
• Overstatement: Myrcene is proven human sedative causing couch-lock.
  More accurate: Plausible preclinical bioactivity, but direct human proof limited [20][23].
• Overstatement: Terpenes have proven entourage effects in patients.
  More accurate: Entourage hypotheses influential but robust clinical proof limited [20][29].
• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself isn’t THC, but heating/processing converts it to THC [12].
• Overstatement: Delta-8 THC is safe because hemp-derived.
  More accurate: Psychoactive, pharmacologically close to delta-9, often tangled with manufacturing/testing concerns [9]-[11].

Practical takeaways for our formulas

• Most evidence-developed: CBD and delta-9 THC
• Not trivial: Delta-8 THC—real pharmacologic activity, incomplete safety characterization
• Changes with processing: THCa chemistry shifts with heating/storage
• Clinically immature: CBG, CBN, CBC—credible but need more research
• Careful with claims: Terpenes—interesting and plausible, but claims should be conservative

References [1]-[29]

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH.
2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy. Exp Neurol. 2023;359:114238.
3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders. Psychiatry Res. 2024;339:116049.
4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in pain treatment. Pharmaceuticals Basel. 2024;17(11):1438.
5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in insomnia management. Cannabis Cannabinoid Res. 2023;8(2):213-229.
6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity. J Intern Med. 2023;293(6):724-752.
7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212.
8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: Comprehensive review. Molecules. 2024;29(22):5471.
9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC. Br J Pharmacol. 2022;179(15):3915-3933.
10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review. Addiction. 2023;118(6):1011-1028.
11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249.
12. Moreno-Sanz G. Can You Pass the Acid Test? Cannabis Cannabinoid Res. 2016;1(1):124-130.
13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain. Ann Intern Med. 2022;175(8):1143-1153.
14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360.
15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol and mental health. Ann Intern Med. 2025;178(10):1429-1440.
16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371.
17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep. Curr Psychiatry Rep. 2024;26(12):712-727.
18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. Potential of cannabichromene as therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213.
19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364.
20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. Entourage effect in cannabis medicinal products. Pharmaceuticals Basel. 2024;17(11):1543.
21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: Multifunctional compound. J Food Biochem. 2021;45(1):e13566.
22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review. Contact Dermatitis. 2022;87(1):1-12.
23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: Potential health benefits. Front Nutr. 2021;8:699666.
24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. Beta-caryophyllene: CB2 receptor-selective properties. Biomed Pharmacother. 2021;140:111639.
25. Weston-Green K, Clunas H, Jimenez Naranjo C. Pinene and linalool as terpene-based medicines for brain health. Front Psychiatry. 2021;12:583211.
26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as therapeutic tool in depression. Curr Neuropharmacol. 2022;20(6):1073-1092.
27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. Clinical translation of alpha-humulene. Planta Med. 2024;90(9):664-674.
28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene. Phytomedicine. 2021;93:153768.
29. Russo EB. Taming THC: Potential cannabis synergy and entourage effects. Br J Pharmacol. 2011;163(7):1344-1364.

RSO SUBLINGUAL OIL FORMULA

Cannabinoid	Amount
CBD	4,500 mg
CBG	3,000 mg
Delta-8 THC	6,000 mg
THCa	1,500 mg
Delta-9 THC	90 mg
CBN	750 mg
CBC	750 mg
Total Cannabinoids	16,590 mg

• Live Terpenes: 5%
• Format: 30 mL bottle
• Active cannabinoids per mL: 553 mg
• Onset: 15-45 minutes
• Duration: 4-6 hours
• Bioavailability: 13-19%
• Doses per bottle: 40-60 (depending on serving size)
• Price: $129.99

For Virgin Islands residents, this formula provides the flexibility to address multiple conditions with one product—chronic pain during the day (raw), sleep support at night (decarbed), chemo nausea as needed (sublingual or vape).

RSO VAPE CARTRIDGE FORMULA

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+
• Format: 1 gram cartridge
• 510-thread battery compatibility
• Onset: 1-2 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35%
• Price: $49.99

For Virgin Islands residents needing fast relief—breakthrough pain, panic attacks, acute nausea—the vape provides near-instant effects that sublingual cannot match.

TERPENE PROFILE (BOTH PRODUCTS)

• Limonene (citrus-bright)
• Myrcene
• Caryophyllene (β-caryophyllene—pepper/spice, CB2 agonist [24])
• Pinene (forest-fresh)
• Linalool (floral, lavender)
• Humulene (earthy, woody)
• Terpinolene (piney, fruity, sparkling)

For Virgin Islanders familiar with local flora—citrus groves, pine forests, spice trees—these terpenes connect the product to sensory experiences you know, making the science tangible through aroma and flavor.

Final thoughts for our Virgin Islands community:

We know that life on St. Thomas, St. John, and St. Croix comes with unique challenges—limited healthcare access, economic pressures, and the isolation of island living. We know that when a hurricane hits, supply chains break and medical appointments get postponed. We know that word-of-mouth travels fast in tight-knit communities, and that trust is earned through consistency, not marketing.

That’s why we’ve published everything. That’s why we ship to the Virgin Islands with full documentation. That’s why we offer the open-source formulas. That’s why we’ve included 35 peer-reviewed citations and seven years of media verification in this document.

Because you deserve the same standard of information that patients in Houston’s Texas Medical Center receive. Because Bentley’s story taught us that cannabinoids can do what pharmaceuticals cannot. Because Colin’s personal journey from borderland hardship to legal industry leader means we understand desperation—and we understand integrity.

The product is $129.99. The knowledge is free. The choice is yours.

Contact us:

• Phone: (832) 416-2816
• Email: [email protected]
• Website: https://oilwellcbd.com/
• Instagram: @oilwellcbd

FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Consult your healthcare provider before use.

Age requirement: 21+ only.

Legal notice: Customer is responsible for understanding and complying with U.S. Virgin Islands law. We assume no legal responsibility for customer’s use or decarboxylation decisions. Void where prohibited.

Safety warning: May cause drowsiness or impairment. Do not operate vehicles or machinery while under the influence. Keep out of reach of children. Consult physician if pregnant or nursing.